Byrd Scott A.

Avg. Two Year Performance

(9%) Avg. Purchase Return
(4%) Compound
No sale track record
1 Mo3 Mo6 Mo1 Yr2 Yr
Average Purchase Return27%(< 1%)(31%)(60%)(9%)
Purchase Success Rate1 of 10 of 10 of 10 of 10 of 1
Average Sale Return6%23%0%0%0%
Sale Success Rate1 of 21 of 20 of 20 of 20 of 2

Cadence Pharmaceuticals Inc.

Drugs » Biotechnology

SVP, Chief Commercial Officer:

Holdings: 0 shares

Sentiment

Insider Trading Sentiment: Hold

Avg. Two Year Performance

No purchase track record
No sale track record

Last Three Months:

0 Net Amount
Buy:0--
Sell:0--